Posts by tag

Pharma Industry

377 posts

New Drug Discovery – Putting Patients First – Asrar Qureshi’s Blog Post #1304

Asrar Qureshi’s Blog Post #1304 highlights Astellas Pharma’s innovative approach to drug development, emphasizing patient-centric decision-making. The company shifts from traditional therapeutic areas to a model based on biology, modality, and disease. Astellas champions learning from failures, cross-functional teams, and harnessing automation to enhance patient outcomes and operational efficiency.
Share
View Post
  • 6 min

Requirements to Reach Pharma C-Suite – Asrar Qureshi’s Blog Post #1300

Asrar Qureshi’s 1300th blog post for Pharma Veterans emphasizes that reaching the C-suite requires more than technical expertise in one area. Aspiring executives must develop cross-functional fluency, build exceptional leaders, and maintain organizational alignment. Success hinges on experience, judgment, and the ability to simplify complex issues for diverse stakeholders.
Share
View Post
  • 6 min

The Exit of Multinational Pharmaceutical Companies from Pakistan – Part 3 – Asrar Qureshi’s Blog Post #1293

Asrar Qureshi’s blog discusses the exit of multinational pharmaceutical companies from Pakistan and the country’s potential to attract them back. Highlighting necessary reforms in pricing, regulation, and clinical research, it stresses a long-term vision for the pharmaceutical sector as vital for economic growth and public health security. Collaboration between domestic and multinational firms is essential for success.
Share
Scientist pipetting liquid into a tray in a laboratory setting with lab equipment and computer displaying graphs
View Post
  • 6 min

Why Multinational Pharmaceutical Companies Are Leaving Pakistan – Asrar Qureshi’s Blog Post #1291

Asrar Qureshi’s blog post discusses the exit of multinational pharmaceutical companies from the Pakistani market, highlighting historical contributions, major exits, and the challenges faced by these firms, such as drug price controls and currency depreciation. Despite local companies acquiring many brands, concerns about access to innovative therapies and a decline in research presence persist.
Share
View Post
  • 6 min

WHO Prequalifies First Ever Malaria Treatment for Newborns and Infants – Asrar Qureshi’s Blog Post #1259

The WHO’s approval of Coartem Baby marks a historic achievement in malaria treatment for newborns and young infants, addressing a critical gap in healthcare. Developed by Novartis and Medicines for Malaria Venture, this innovative drug provides a safer, accurately dosed option, highlighting the importance of inclusive pharmaceutical innovation and collaborative efforts in global health.
Share
View Post
  • 5 min

Cost of Incentives to Work Life Balance – Asrar Qureshi’s Blog Post #1258

Asrar Qureshi’s Blog Post 1257 discusses the impact of performance incentives in the pharmaceutical industry. While rewards drive productivity, they can also lead to work-life imbalance, burnout, and a narrow definition of success, emphasizing metrics over well-being. The post advocates for redesigning incentives to promote sustainable practices and prioritize employee wellness.
Share
View Post
  • 6 min

Doctors & Pharma Industry – Part 2 of 2 – Asrar Qureshi’s Blog Post #1218

Asrar Qureshi’s Blog Post #1218 addresses the complex relationship between pharmaceutical companies and doctors, emphasizing the need for ethical conduct in Pakistan’s healthcare system. It outlines a Code of Conduct for both sectors, aiming to balance industry collaboration with patient welfare, maintaining professionalism while avoiding conflicts of interest.
Share
View Post
  • 5 min

Doctors & Pharma Industry – Part 1 of 2 – Asrar Qureshi’s Blog Post 1217

The blog post by Asrar Qureshi explores the complex relationship between pharmaceutical companies and doctors, emphasizing its dual nature of necessity and ethical risk. It advocates for transparency and independence in education, particularly in the context of Pakistan’s healthcare challenges. The post highlights both issues and contributions of this relationship in improving patient access to treatment.
Share